Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Andrew Ko, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address550 16th Street
    San Francisco CA 94158
    Phone415-353-7286
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites
      Collapse NIH Awarded Grants
      Collapse Clinical Trials
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Ko AH, Bekaii-Saab T, van Ziffle J, Mirzoeva OK, Joseph N, Talasaz A, Kuhn P, Tempero MA, Collisson E, Kelley RK, Venook A, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM, et al. A MULTICENTER, OPEN-LABEL PHASE II CLINICAL TRIAL OF COMBINED MEK PLUS EGFR INHIBITION FOR CHEMOTHERAPY-REFRACTORY ADVANCED PANCREATIC ADENOCARCINOMA. Clin Cancer Res. 2015 Aug 6. PMID: 26251290.
        View in: PubMed
      2. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. PMID: 26109333.
        View in: PubMed
      3. Pollom EL, Koong AC, Ko AH. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):741-59. PMID: 26226908.
        View in: PubMed
      4. Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015 Jun 1; 33(16):1779-86. PMID: 25918299.
        View in: PubMed
      5. Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study. Cancer. 2015 Apr 15; 121(8):1287-94. PMID: 25649483.
        View in: PubMed
      6. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; 35:e222-7. PMID: 25993177.
        View in: PubMed
      7. Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014 Dec; 5(6):E88-95. PMID: 25436138.
        View in: PubMed
      8. Walker EJ, Ko AH, Holly EA, Bracci PM. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer. 2015 Mar 15; 136(6):E646-53. PMID: 25091126.
        View in: PubMed
      9. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. PMID: 25099441.
        View in: PubMed
      10. Walker EJ, Simko JP, Ko AH. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014 Jul; 34(7):3629-34. PMID: 24982379.
        View in: PubMed
      11. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. PMID: 24448917.
        View in: PubMed
      12. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. PMID: 24622062; PMCID: PMC3955845 [Available on 04/01/15].
      13. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6. PMID: 24633933.
        View in: PubMed
      14. Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014 Mar 7; 20(9):2224-36. PMID: 24605022; PMCID: PMC3942828.
      15. Cinar P, Ko AH. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2014 Feb; 12(2):167-72. PMID: 24586078.
        View in: PubMed
      16. Ko AH. Expanding options for pancreatic cancer... so where do we go from here? Oncology (Williston Park). 2014 Jan; 28(1):5. PMID: 24683713.
        View in: PubMed
      17. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34. PMID: 24022191; PMCID: PMC3790192.
      18. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013 Oct; 12(10):2213-25. PMID: 23918833; PMCID: PMC3800201.
      19. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5. PMID: 23880820; PMCID: PMC3749576.
      20. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7. PMID: 23519998; PMCID: PMC3690907.
      21. Ko AH, Cella D. Achieving the best of both worlds. J Clin Oncol. 2013 Jan 1; 31(1):3-4. PMID: 23213099.
        View in: PubMed
      22. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. PMID: 21552099.
        View in: PubMed
      23. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. PMID: 23053263.
        View in: PubMed
      24. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):703-13. PMID: 22679115; PMCID: PMC3807091.
      25. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. PMID: 22306705; PMCID: PMC3387999.
      26. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. PMID: 22306768; PMCID: PMC3387996.
      27. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 1; 30(1):88-109. PMID: 22147736.
        View in: PubMed
      28. Ko AH. FOLFIRINOX: a small step or a great leap forward? J Clin Oncol. 2011 Oct 1; 29(28):3727-9. PMID: 21900100.
        View in: PubMed
      29. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1597-606. PMID: 21629990.
        View in: PubMed
      30. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. PMID: 21460848; PMCID: PMC3755490.
      31. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91. PMID: 21245436.
        View in: PubMed
      32. Ko AH, Crane CH. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw. 2010 Sep; 8(9):1022-31. PMID: 20876542.
        View in: PubMed
      33. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. PMID: 20130876.
        View in: PubMed
      34. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
      35. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. PMID: 19041649.
        View in: PubMed
      36. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. PMID: 18815548.
        View in: PubMed
      37. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. PMID: 18379729.
        View in: PubMed
      38. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95. PMID: 19707431; PMCID: PMC2727779.
      39. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. PMID: 18181045.
        View in: PubMed
      40. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72. PMID: 17893568.
        View in: PubMed
      41. Ko AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol. 2007 Aug; 34(4):354-64. PMID: 17674964.
        View in: PubMed
      42. Ko AH, Wang F, Holly EA. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control. 2007 Oct; 18(8):809-19. PMID: 17632765.
        View in: PubMed
      43. Lam K, Lam FK, Lau KK, Chan YK, Kan EY, Woo J, Wong FK, Ko A. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. Mov Disord. 2007 Apr 15; 22(5):640-4. PMID: 17266075.
        View in: PubMed
      44. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 1; 68(3):809-16. PMID: 17363191.
        View in: PubMed
      45. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. PMID: 16344320.
        View in: PubMed
      46. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. PMID: 16183478.
        View in: PubMed
      47. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. PMID: 16194454.
        View in: PubMed
      48. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. PMID: 15999098; PMCID: PMC2361548.
      49. Ko AH, Bergsland EK, Lee GA. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):192-6. PMID: 12645810.
        View in: PubMed
      50. Ko AH, Yuen AR. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma. 2002 Sep; 43(9):1789-93. PMID: 12685833.
        View in: PubMed
      51. Ko AH, Tempero MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. PMID: 11937010.
        View in: PubMed
      52. Harmon EB, Ko AH, Kim SK. Hedgehog signaling in gastrointestinal development and disease. Curr Mol Med. 2002 Feb; 2(1):67-82. PMID: 11898849.
        View in: PubMed
      53. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP. AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol. 2002 Jan; 16(1):85-99. PMID: 11773441.
        View in: PubMed
      54. Chen Z, Ko A, Yang J, Jordan VC. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. Br J Cancer. 1998; 77(2):181-5. PMID: 9460986; PMCID: PMC2151219.
      55. Gallant JE, Ko AH. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr; 22(4):671-82. PMID: 8729207.
        View in: PubMed
      56. Ko AH, Thomas DL, Gallant JE. Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor. AIDS. 1995 Oct; 9(10):1195-7. PMID: 8519459.
        View in: PubMed
      57. Ko AH. Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China. Pharos Alpha Omega Alpha Honor Med Soc. 1994; 57(2):11-5. PMID: 8022868.
        View in: PubMed
      Andrew's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP